middle.news
How Tetratherix’s $9.4M Loss Sets Stage for Breakthroughs in Regenerative Medicine
2:12am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Tetratherix’s $9.4M Loss Sets Stage for Breakthroughs in Regenerative Medicine
2:12am on Saturday 30th of August, 2025 AEST
Key Points
FY25 statutory loss widened to $9.4 million from $2.55 million in FY24
Raised $25 million in IPO, listing on ASX in June 2025
Advanced clinical trials across Bone Regeneration, Tissue Spacing, and Tissue Healing franchises
Secured $3.3 million Australian Government Industry Growth Program grant
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Tetratherix (ASX:TTX)
OPEN ARTICLE